

1 **RULES OF PROCEDURE OF THE EUROPEAN PHARMACOPOEIA COMMISSION**

2 These Rules of Procedure have been revised by the European Pharmacopoeia Commission in
3 accordance with Article 5, Paragraph 2 of the *Convention on the Elaboration of a European*
4 *Pharmacopoeia*.

5 The "European Pharmacopoeia Commission", hereinafter called "the Commission", shall
6 proceed in accordance with the provisions of the "*Convention on the Elaboration of a European*
7 *Pharmacopoeia*" hereinafter called "the Convention" as amended by the Protocol that entered
8 into force on 1 November 1992. In the context of this document, "*expert from Ph. Eur. Member*
9 *State*" means a person nominated by a Contracting Party wherever he/she is working and
10 irrespective of his/her nationality, and "*expert from non-Ph. Eur. Member State*" means any
11 other expert showing interest in participating in the work of the Ph. Eur.

12 The *Rules of procedure of the European pharmacopoeia* are complemented by the *Guide for*
13 *work of the European pharmacopoeia* and the *Code of Practice for the work of the European*
14 *Pharmacopoeia*.

15 *All references in these Rules of Procedure to functions, titles or positions shall be construed as*
16 *applying equally to men and women.*

17 **INDEX**

18	2.	FUNCTIONS OF THE COMMISSION	4
19	3.	CHAIR OF THE COMMISSION.....	4
20	4.	VICE-CHAIRS	5
21	5.	PRESIDIUM.....	5
22	6.	DUTIES OF THE CHAIR OF THE COMMISSION.....	5
23	7.	DUTIES OF THE PRESIDIU.....	6
24	8.	CONTRACTING PARTIES TO THE CONVENTION	6
25	9.	SECRETARIAT	6
26	10.	GROUPS OF EXPERTS AND WORKING PARTIES	7
27	11.	CONSULTATIONS.....	8
28	12.	OBSERVERS	8
29	13.	SESSIONS AND AGENDA OF THE COMMISSION	9
30	14.	MEETINGS OF THE GROUPS OF EXPERTS AND WORKING PARTIES	10
31	15.	REPORTS OF THE COMMISSION	10
32	16.	LANGUAGES	10
33	17.	QUORUM	10

34	18.	INTRODUCTION, REVISION OR SUPPRESSION OF TEXTS IN/OF THE EUROPEAN PHARMACOPOEIA	
35		11	
36	19.	REVISION OF the RULES OF PROCEDURE	11
37			
38			

39 MEMBERSHIP OF THE COMMISSION

40 1.1 The Commission shall be composed of delegations appointed in pursuance of Article 5 of
41 the Convention. The members of the Commission are the members of these
42 delegations.

43 1.2 The alternates referred to in Article 5 of the Convention shall sit on the Commission only
44 when the members of delegations are prevented from doing so and for that purpose
45 become members of the Commission.

46 1.3 A *curriculum vitae* and a declaration of interests shall accompany all appointments of
47 members and of alternates referred to in Article 5 of the Convention.

48 2. FUNCTIONS OF THE COMMISSION

49 2.1 In pursuance of subparagraphs a) and c) of Article 6 of the Convention, the Commission
50 decides on the work programme for the elaboration of the European Pharmacopoeia
51 and decides the general policies to be applied in the work. To this end, the Commission
52 prepares a public mission statement defining the role and purpose of the European
53 Pharmacopoeia and draws up its own Rules of Procedure.

54 2.2 The Commission may appoint Groups of Experts and Working Parties.

55 2.3 The Commission has the ultimate responsibility for the progress of the work that has
56 been decided upon and for ensuring that these Rules, the *Guide for the Work* and the
57 *Code of Practice of the European Pharmacopoeia* are followed.

58 2.4 The Commission evaluates proposals for inclusion, revision or suppression of
59 monographs and general chapters. The Commission defines criteria for setting priorities
60 for the work programme.

61 2.5 The Commission allocates agreed work items to a Group of Experts or Working Party and
62 makes an annual review of overall progress with the work programme, including
63 revision work.

64 2.6 The Commission approves the terms of reference of Groups of Experts and Working
65 Parties, defines criteria to be applied in the selection of experts and *ad hoc* specialists
66 and approves the composition of Groups of Experts and Working Parties, based on the
67 proposals made by the Presidium.

68 3. CHAIR OF THE COMMISSION

69 3.1 The Chair of the Commission shall be elected by a two-thirds majority of the votes cast
70 by the delegations in a secret ballot in accordance with paragraph 3 of Article 5 of the
71 Convention; two tellers appointed by acclamation shall count the votes cast.

72 Candidatures for the Chair shall be submitted in writing to the Secretariat not later than
73 28 days before the beginning of the Session at which an election is to take place. Not
74 later than 21 days before the beginning of the Session, the Secretariat shall notify the
75 delegations in writing of candidatures received.

76 Votes cast for persons whose candidature has not been declared in accordance with the
77 preceding paragraph shall be considered void.

78 Candidatures shall be accompanied by a *curriculum vitae* and a statement of motivation.

79 3.2 The term of office of the Chair shall be three years. He shall not immediately be eligible
80 thereafter for re-election. His successor shall be elected at the last meeting of the
81 Commission in the aforementioned period of three years; he shall not, however, take up
82 his duties until this period has expired.

83 3.3 Upon taking up his duties, the Chair shall at once cease to be a member of his
84 delegation; the latter may then be completed in accordance with Rule 1.2 of these Rules
85 of Procedure.

86 3.4 If, during his term of office, the Chair becomes permanently unable to continue his
87 duties, the first or, if he is not available, the second Vice-Chair shall act in his place until
88 a new Chair is elected at the next Session of the Commission. The Chair so elected shall
89 hold office for the rest of the term and can be re-elected for another full term.

90 4. VICE-CHAIRS

91 4.1 The Commission shall elect two Vice-Chairs who shall fulfil the duties of the Chair when
92 he is absent or temporarily unable to discharge his duties. The Vice-Chairs are elected in
93 order of their precedence.

94 4.2 The provisions of Rules 3.1 and 3.2 of these Rules of Procedure shall apply *mutatis*
95 *mutandis* to the election and term of office of the Vice-Chairs.

96 4.3 When a Vice-Chair is requested to take over the chair of a Session, the Vice-Chair ceases
97 to be a member of his delegation; the latter may then be completed in accordance with
98 the provisions of Rule 1.2 of these Rules of Procedure.

99 5. PRESIDIUM

100 5.1 The Presidium consists of the Chair and the two Vice-chairs; they are assisted by the
101 Director of the European Directorate for the Quality of Medicines and HealthCare
102 (EDQM) and the Secretary to the Commission.

103 6. DUTIES OF THE CHAIR OF THE COMMISSION

104 6.1 The Chair of the Commission decides, in consultation with the Director of the EDQM and
105 the Secretary to the Commission and, where necessary the Vice-Chairs, the draft agenda
106 for a session.

107 6.2 The Chair, at Sessions of the Commission, shall direct the proceedings and announce
108 decisions. He shall call to order any speaker whose observations are not relevant to the
109 subject under discussion or not within the terms of reference of the Commission.

110 6.3 During the period between sessions, the Chair shall oversee the work of the Commission
111 and, where necessary, act in consultation with the other members of the Presidium on
112 behalf of the Commission.

113 7. DUTIES OF THE PRESIDIUM

114 7.1 The Presidium participates in the preparatory work between sessions. It shall collectively
115 endeavour to prepare the items to be discussed by the Commission to facilitate the
116 decision-making process. The Presidium may hold meetings between sessions for this
117 purpose. A report of such meetings shall be prepared by the Secretariat.

118 7.2 The Presidium upon appointment prepares for consideration by the Commission a set of
119 proposals concerning the general policy and role of the European Pharmacopoeia,
120 criteria for prioritisation of work and a set of priorities for the coming three years. After
121 each Session of the Commission, the Presidium may review the work programme for
122 reconsideration by the Commission.

123 7.3 The Presidium prepares for consideration by the Commission a set of proposals
124 concerning the terms of reference of Groups of Experts and Working Parties and the
125 appropriate selection criteria for the nomination of Experts and *ad hoc* Specialists to
126 each Group of Experts and Working Party.

127 7.4 In accordance with rule 7.3 the Presidium, based on candidatures sent by each
128 Contracting Party, by Observers or by the Secretariat, prepares for consideration by the
129 Commission a proposal for the composition of Groups of Experts and Working Parties.

130 8. CONTRACTING PARTIES TO THE CONVENTION

131 8.1 Each Contracting Party shall notify the Secretariat of the responsible authority for the
132 implementation of the decisions of the Commission in its respective country as foreseen
133 under Article 1 of the Convention (National Pharmacopoeia Authority, NPA), the
134 responsible person at the NPA and the relevant contact details.

135 9. SECRETARIAT

136 9.1 The Secretariat shall prepare the Sessions of the Commission and the meetings of the
137 Groups of Experts and Working Parties in consultation with the respective Chairs and
138 shall draft the summaries and reports of them in accordance with the provisions of the
139 *Guide for the Work of the European Pharmacopoeia*. It shall be responsible for the
140 preparation and distribution of all documents and other written communications
141 intended to be studied by the Commission, the Groups of Experts or the Working
142 Parties. All documents issued by the Secretariat shall be sent to the Presidium of the
143 Commission, to the address of the responsible contact person(s) named by each
144 Contracting Party, and, as appropriate, to members of each delegation, Group of Experts
145 or Working Party.

146 9.2 The Secretariat shall be responsible for the publication of monographs, general chapters
147 and other official texts adopted by the Commission; each publication shall be issued in
148 the two official languages.

149 9.3 Immediately after the adoption by the European Committee on Pharmaceuticals and
150 Pharmaceutical Care (CD-P-PH) of a Resolution giving effect to the date of
151 implementation or suppression of texts, the Secretariat shall notify the Contracting
152 Parties.

153 9.4 The Secretariat shall be responsible for establishing and maintaining appropriate contact
154 with the laboratories to which the Commission has decided to entrust certain work. The
155 Secretariat shall contribute to the work on elaboration of monographs and general
156 chapters. The Secretariat shall organise the preparation, the establishment, the
157 maintenance and the replacement of batches of reference standards.

158 9.5 The Secretary General of the Council of Europe or his representative, the Director of the
159 EDQM and the Secretary to the Commission may, at any time, make a statement on any
160 subject under discussion.

161 **10. GROUPS OF EXPERTS AND WORKING PARTIES**

162 10.1 The Commission appoints Groups of Experts and Working Parties, for a period of three
163 years unless otherwise defined by the Commission. Groups of Experts cover the main
164 scientific disciplines of quality control of medicinal products and their constituents.
165 Working Parties deal with a specific aspect of the work or with a specific topic and are
166 normally appointed for a defined period.

167 10.2 Each Group of Experts or Working Party has Terms of Reference. These Terms of
168 Reference are proposed by the Presidium and approved by the Commission.

169 10.3 Each Group of Experts or Working Party has a work programme defined by the
170 Commission. Progress on the work programme is reviewed annually by the Commission.

171 10.4 Groups of Experts report directly to the Commission. Working Parties report directly to
172 the Commission unless otherwise decided.

173 10.5 Groups of Experts and Working Parties are comprised of experts and if applicable, *ad*
174 *hoc* specialists having current scientific and/or technical knowledge to cover the duties
175 described in the Terms of Reference.

176 **10.6 Chairs of Groups of Experts and Working Parties**

177 10.6.1 Each Contracting Party may propose one candidate for appointment as Chair of a Group
178 of Experts or Working Party, taking account of his competence for the work involved
179 and of his past contribution. The candidate shall preferably be a member of the
180 Commission.

181 10.6.2 The Chair of a Group of Experts or Working Party shall be elected by the Commission by
182 a majority of the delegations casting a vote.

183 10.6.3 Following the election of the Chair and the Vice Chairs of the Commission, the
184 Commission appoints the Chairs of Groups of Experts and Working Parties for a period
185 of three years unless otherwise defined by the Commission. In order to make a fair
186 distribution of Chairs between the delegations and to provide for a reasonable rotation
187 in the responsibilities, a person may be appointed to not more than two successive
188 terms of office as Chair of a given Group of Experts and only exceptionally, where no
189 other candidate is available, to a third successive term.

190 10.6.4 The term of office of the Chair of a Working Party is the defined period of its activities,
191 and shall in any case be reviewed following the election of the Chair and the Vice-
192 Chairs of the Commission.

193 10.7 **Experts, *ad hoc* specialists and substitutes**

194 10.7.1 Experts or *ad hoc* specialists are proposed for appointment to Groups of Experts or
195 Working Parties, taking account of their competence for the work involved.

196 10.7.2 Experts from Ph. Eur. Member States are proposed by a Contracting Party. Applications
197 of experts from non-Ph. Eur. Member States are directly addressed to the Secretariat.

198 10.7.3 *Ad hoc* specialists are proposed by a Contracting Party, by the Secretariat or by a
199 member of the Group of Experts or Working Party.

200 10.7.4 When an appointed expert or *ad hoc* specialist from a Ph. Eur. Member State is unable
201 to attend a meeting, the Contracting Party may send a substitute and, in this case, shall
202 inform the Secretariat and the Chair of the Group of Experts or Working Party
203 accordingly.

204 10.7.5 Substitutes from non-Ph. Eur. Member States are not allowed unless decided so by the
205 Commission or, in urgent cases, by its Chair.

206 **11. CONSULTATIONS**

207 11.1 The Commission may decide to hear the representatives of associations or scientific
208 institutions.

209 11.2 It may also decide to seek the advice of consultants.

210 **12. OBSERVERS**

211 12.1 The European Committee on Pharmaceuticals and Pharmaceutical Care (previously the
212 Public Health Committee referred to in sub-paragraph a) of Article 2 of the Convention)

213 may arrange to be represented at the sessions of the Commission by an observer; the
214 latter shall have the right to speak and to make proposals.

215 12.2 The Commission may also, by a unanimous vote of the delegations casting a vote admit
216 to some of its sessions technically qualified observers, such as:

217 (a) observers from Member States of the Council of Europe that are not parties to the
218 Convention;

219 (b) observers from States that are not Members of the Council of Europe;

220 (c) observers from international governmental organisations;

221 (d) observers from international non-governmental organisations.

222 12.3 The observers referred to in Rule 12.2 shall have the right to speak; they may not,
223 however, make proposals unless these are put forward by one of the delegations
224 referred to in Rule 1 of these Rules of Procedure.

225 **13. SESSIONS AND AGENDA OF THE COMMISSION**

226 13.1 The Commission shall hold its Sessions in Strasbourg, the seat of the Council of Europe.

227 13.2 The Commission shall sit whenever necessary but at least twice a year; it shall be
228 convened on behalf of and at the request of the Chair of the Commission by the
229 Secretariat at least 21 days before the opening of each Session. The Chair of the
230 Commission must convene the Commission if three quarters of the delegations so
231 request.

232 13.3 Once a Session has been convened in accordance with this Rule 13.2, any request for
233 postponement must reach the Secretariat at least 21 days before the date set for the
234 opening of the Session. A decision to postpone the Session shall be deemed to have
235 been taken if three quarters of the delegations shall have informed the Secretariat of
236 their agreement 14 days before the date originally set. A decision to advance the date of
237 the Session shall be deemed to have been taken only when all the delegations have
238 informed the Secretariat of their agreement, at least 14 days before the new date
239 proposed.

240 13.4 The agenda shall be adopted at the beginning of each Session on the basis of a draft
241 which the Secretariat of the Commission shall prepare in consultation with the
242 Commission's Chair and send to the delegations at least 21 days before the opening of
243 the Session. An addendum to the agenda may be provided to delegations prior to the
244 beginning of the Session and adopted by the Commission as part of the final agenda.

245 13.5 A delegation to the Commission may request that discussion of a document be
246 postponed if it has not been distributed by the Secretariat sufficiently in advance of the
247 Session.

248 13.6 Sessions of the Commission shall be held in private.

249 **14. MEETINGS OF THE GROUPS OF EXPERTS AND WORKING PARTIES**

250 14.1 Groups of Experts and Working Parties shall hold their meetings in Strasbourg, unless
251 otherwise justified. If it is proposed to hold a meeting elsewhere, the Chair should make
252 a request in writing to the Director of EDQM providing justification for this in terms of
253 the contribution to the advancement of the work of the group. The Director of the
254 EDQM will consult National Pharmacopoeia Authorities before taking a decision.

255 14.2 Meetings of the Groups of Experts and Working Parties shall be held in private.

256 **15. REPORTS OF THE COMMISSION**

257 15.1 After each Session of the Commission, the Secretariat shall issue a summary of decisions
258 promptly and prepare a report. It shall give the text of and, where appropriate, the
259 grounds for all decisions taken by the Commission, particularly those relating to:

260 (a) the general principles to be applied in elaborating the European Pharmacopoeia;

261 (b) the relevant methods of analysis;

262 (c) the monographs provided for in Article 6 of the Convention and intended to be
263 included in the European Pharmacopoeia.

264 15.2 The report shall include, where necessary:

265 (a) the name of each monograph adopted and the reference number of the document
266 in which the text appears, together with the text of any adopted amendments to
267 that document;

268 (b) the dates of entry into force recommended in accordance with subparagraph d of
269 Article 6 of the Convention.

270 15.3 Each final report shall be submitted for approval by the Commission at the Session
271 following that to which it refers and shall then be transmitted to the European
272 Committee on Pharmaceuticals and Pharmaceutical Care in accordance with Article 4 of
273 the Convention.

274 **16. LANGUAGES**

275 16.1 The working languages of the Commission shall be the official languages of the Council
276 of Europe.

277 16.2 Any delegate may speak in a language other than the official languages, provided he
278 himself arranges for interpretation into one of the official languages.

279 **17. QUORUM**

280 17.1 The decisions of the Commission shall be valid only if a majority of the delegations is
281 present.

282 17.2 Each delegation may at its request be represented by another delegation. In such a case
283 the delegation represented shall be considered as present for the purposes of quorum
284 and voting. A delegation wishing to be so represented shall inform the Secretariat in
285 writing before the vote (see form in Annex). The Secretariat shall inform the tellers if any
286 delegation has chosen to be so represented.

287 **18. INTRODUCTION, REVISION OR SUPPRESSION OF TEXTS IN/OF THE EUROPEAN**
288 **PHARMACOPOEIA**

289 18.1 Proposals concerning the introduction, revision or suppression of monographs, general
290 chapters and other texts in/of the European Pharmacopoeia may be made by e.g.:

291 — the Chair of the Commission,

292 — a delegation,

293 — a National Pharmacopoeia Authority,

294 — a Group of Experts or Working Party through the intermediary of its Chair,

295 — the Secretariat,

296 — manufacturers and other interested parties from Member States through the
297 intermediary of their National Pharmacopoeia Authority,

298 — manufacturers and other interested parties from Observer States through the
299 intermediary of a National Pharmacopoeia Authority or the Secretariat,

300 — manufacturers and other interested parties from non-Member or non-Observer
301 States through the intermediary of the Secretariat.

302 18.2 The procedures to be followed for the elaboration, revision and suppression of texts for
303 the European Pharmacopoeia are laid down in the *Guide for the Work of the European*
304 *Pharmacopoeia*.

305 **19. REVISION OF THE RULES OF PROCEDURE**

306 19.1 These Rules of Procedure may be amended at any time.

307 19.2 Amendments thereto shall require a three-quarters majority in accordance with
308 paragraph 3 of Article 7 of the Convention.

309

310

Annex

311

EUROPEAN PHARMACOPOEIA COMMISSION

312

Rule of Procedure 17.2: representation of one delegation by another

313

Form to be submitted to the Secretariat by a delegation wishing to be represented by another

314

for the purposes of voting

315

Delegation:

316

317

Representative of the delegation (name, date and signature):

318

319

320

The above delegation will be represented by the following delegation as provided for in the

321

Rule of Procedure 17.2:

322

323

Representing delegation:

324

325

Representative of the representing delegation (name, date and signature):

326

327

328

Valid for:

329

330

Session (number):

331

332

Date(s) on which the delegation is to be represented:

333

334

335

Agenda items (please indicate "all agenda items" or specific one or more items):